Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
J Cardiovasc Electrophysiol. 2023 Apr;34(4):1006-1014. doi: 10.1111/jce.15882. Epub 2023 Mar 16.
We aimed to investigate the impact of the 2021 European Society of Cardiology (ESC) guideline changes in left bundle branch block (LBBB) definition on cardiac resynchronization therapy (CRT) patient selection and outcomes.
The MUG (Maastricht, Utrecht, Groningen) registry, consisting of consecutive patients implanted with a CRT device between 2001 and 2015 was studied. For this study, patients with baseline sinus rhythm and QRS duration ≥ 130ms were eligible. Patients were classified according to ESC 2013 and 2021 guideline LBBB definitions and QRS duration. Endpoints were heart transplantation, LVAD implantation or mortality (HTx/LVAD/mortality) and echocardiographic response (LVESV reduction ≥15%).
The analyses included 1.202, typical CRT patients. The ESC 2021 definition resulted in considerably less LBBB diagnoses compared to the 2013 definition (31.6% vs. 80.9%, respectively). Applying the 2013 definition resulted in significant separation of the Kaplan-Meier curves of HTx/LVAD/mortality (p < .0001). A significantly higher echocardiographic response rate was found in the LBBB compared to the non-LBBB group using the 2013 definition. These differences in HTx/LVAD/mortality and echocardiographic response were not found when applying the 2021 definition.
The ESC 2021 LBBB definition leads to a considerably lower percentage of patients with baseline LBBB then the ESC 2013 definition. This does not lead to better differentiation of CRT responders, nor does this lead to a stronger association with clinical outcomes after CRT. In fact, stratification according to the 2021 definition is not associated with a difference in clinical or echocardiographic outcome, implying that the guideline changes may negatively influence CRT implantation practice with a weakened recommendation in patients that will benefit from CRT.
我们旨在研究 2021 年欧洲心脏病学会(ESC)左束支传导阻滞(LBBB)定义变化对心脏再同步治疗(CRT)患者选择和结局的影响。
本研究纳入了 2001 年至 2015 年间连续植入 CRT 设备的患者组成的 MUG(马斯特里赫特、乌得勒支、格罗宁根)注册研究。本研究中,基线窦性心律和 QRS 持续时间≥130ms 的患者符合条件。患者根据 ESC 2013 年和 2021 年指南 LBBB 定义和 QRS 持续时间进行分类。终点是心脏移植、LVAD 植入或死亡率(HTx/LVAD/死亡率)和超声心动图反应(LVESV 减少≥15%)。
分析包括 1202 例典型 CRT 患者。与 2013 年定义相比,ESC 2021 年定义导致 LBBB 诊断明显减少(分别为 31.6%和 80.9%)。应用 2013 年定义可显著分离 HTx/LVAD/死亡率的 Kaplan-Meier 曲线(p<0.0001)。与非 LBBB 组相比,应用 2013 年定义时,LBBB 组的超声心动图反应率显著更高。当应用 2021 年定义时,这些 HTx/LVAD/死亡率和超声心动图反应的差异并不明显。
ESC 2021 年 LBBB 定义导致基线 LBBB 患者的比例明显低于 ESC 2013 年定义。这不能更好地区分 CRT 反应者,也不能与 CRT 后临床结局更强相关。事实上,根据 2021 年定义进行分层与临床或超声心动图结果无差异,这意味着指南的改变可能会对 CRT 植入实践产生负面影响,对那些将从 CRT 中获益的患者的推荐减弱。